Earnings ·
Reports Q3 net loss of $10.5M, or $(0.15) per share, and $469.9M cash
BCYCBicycle Therapeutics PLC
Bicycle Therapeutics reported a third-quarter 2026 net loss of $10.5 million, or $(0.15) basic and diluted loss per share, compared to a $59.1 million loss in the prior-year period. The company held $469.9 million in cash and cash equivalents as of September 30, 2026, with an expected cash runway extending into 2030. Collaboration revenue increased to $34.1 million from $11.7 million due to the recognition of remaining revenue upon the termination of a collaboration agreement with Bayer Consumer Care AG. Research and development expenses decreased to $33.4 million from $58.4 million, primarily driven by workforce reductions and lower clinical program costs. The company also announced that nuzefatide pevedotin received FDA Orphan Drug Designation for pancreatic cancer and plans to initiate its first company-sponsored radioligand clinical trial for BT1702 in the second half of 2027. Bicycle Therapeutics is a clinical-stage pharmaceutical company developing novel bicyclic peptide therapeutics.